IS8587A - Atorvastatin pharmaceutical combination - Google Patents
Atorvastatin pharmaceutical combinationInfo
- Publication number
- IS8587A IS8587A IS8587A IS8587A IS8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A
- Authority
- IS
- Iceland
- Prior art keywords
- pharmaceutical combination
- atorvastatin pharmaceutical
- atorvastatin
- combination
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8587A IS8587A (en) | 2006-12-27 | 2006-12-27 | Atorvastatin pharmaceutical combination |
| EP07849693A EP2124899A2 (en) | 2006-12-27 | 2007-12-21 | Stable pharmaceutical formulations of atorvastatin magnesium salt |
| PCT/IS2007/000024 WO2008078341A2 (en) | 2006-12-27 | 2007-12-21 | Stable pharmaceutical formulations of atorvastatin magnesium salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8587A IS8587A (en) | 2006-12-27 | 2006-12-27 | Atorvastatin pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8587A true IS8587A (en) | 2008-06-28 |
Family
ID=39473858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8587A IS8587A (en) | 2006-12-27 | 2006-12-27 | Atorvastatin pharmaceutical combination |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2124899A2 (en) |
| IS (1) | IS8587A (en) |
| WO (1) | WO2008078341A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2130819A3 (en) * | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Crystalline forms of atorvastatin magnesium |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003245736A1 (en) * | 2002-02-14 | 2003-09-04 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
| CA2588216A1 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| US20080305158A1 (en) * | 2004-12-28 | 2008-12-11 | Ranbaxy Laboratories Limited | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine |
| EP2172452A1 (en) * | 2005-05-03 | 2010-04-07 | Ranbaxy Laboratories Limited | Preparation of crystalline atorvastatin magnesium |
| US20100168201A1 (en) * | 2005-11-29 | 2010-07-01 | Biocan Limited | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1) |
| SI22255A (en) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | New polymorphs of statine salts and their application in pharmaceutical formulations |
| JP2009536638A (en) * | 2006-05-11 | 2009-10-15 | バイオコン リミテッド | Crystalline form B4 of atorvastatin magnesium and method thereof |
-
2006
- 2006-12-27 IS IS8587A patent/IS8587A/en unknown
-
2007
- 2007-12-21 WO PCT/IS2007/000024 patent/WO2008078341A2/en active Application Filing
- 2007-12-21 EP EP07849693A patent/EP2124899A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2124899A2 (en) | 2009-12-02 |
| WO2008078341A2 (en) | 2008-07-03 |
| WO2008078341A3 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2140867I2 (en) | Pharmaceutical composition | |
| DK2041139T3 (en) | Pharmaceutical compounds | |
| BRPI0715712A2 (en) | PHARMACEUTICAL COMPOSITION | |
| BRPI0719393A2 (en) | Pharmaceutical Composition | |
| RU2398586C3 (en) | PHARMACEUTICAL COMPOSITION | |
| DK1957073T3 (en) | PHARMACEUTICAL | |
| DK2384754T3 (en) | Pharmaceutical dosage forms | |
| BRPI0721651A2 (en) | PHARMACEUTICAL COMPOSITION | |
| BRPI0920521A2 (en) | pharmaceutical combination | |
| DK2073795T3 (en) | Abuse-safe drug formulation | |
| DK1986650T3 (en) | MANIPULATION-SAFE DOSAGE FORMS | |
| CR10841A (en) | IMIDAZOTRIAZINAS IMIDAZOPIRIMIDINAS INHIBIDORES DE CINASA | |
| BRPI0716445A2 (en) | pharmaceutical composition | |
| BRPI0720234A2 (en) | PHARMACEUTICAL COMPOSITION | |
| AT504580A3 (en) | SCAN-DEVICE | |
| ATE546437T1 (en) | AMINOMETHYL-4-IMIDAZOLE | |
| DK2120884T3 (en) | Pharmaceutical composition | |
| DK2035369T3 (en) | THERAPEUTIC | |
| DE502007000218D1 (en) | nsetzungen | |
| BRPI0719394A2 (en) | Solid medicinal preparation | |
| DE502007001629D1 (en) | RFAHREN | |
| DE502007000361D1 (en) | Stanznieteinheit | |
| DE102006045567A8 (en) | Crimpstabilisierung | |
| BRPI0716742A2 (en) | Therapeutic Lactams | |
| DE112007003147A5 (en) | Pipe-bender |